The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: A new statistical model

American Journal of Clinical Pathology

Volumn 137, Issue 3, 2012, Pages 377-386

  Cannizzo, Elisa ^a   Carulli, Giovanni ^a   Del Vecchio, Luigi ^b   Ottaviano, Virginia ^a   Bellio, Emanuele ^a   Zenari, Ezio ^a   Azzarà, Antonio ^a   Petrini, Mario ^a   Preffer, Frederic ^c  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

CD19 and CD27 expression; Flow cytometry; Multiple myeloma

Indexed keywords

CD19 ANTIGEN; CD27 ANTIGEN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; MULTIPLE MYELOMA; PRIORITY JOURNAL; TREATMENT RESPONSE; BONE MARROW; BONE MARROW TRANSPLANTATION; CELL CLONE; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSPECTIVE STUDY; STATISTICAL MODEL; TREATMENT OUTCOME;

ANTIGENS, CD19; ANTIGENS, CD27; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BONE MARROW TRANSPLANTATION; CLONE CELLS; COMBINED MODALITY THERAPY; FLOW CYTOMETRY; HUMANS; MODELS, STATISTICAL; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84859235361     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP63TOCFNAMDMS     Document Type: Article

References (49)

1. Munker R, Hiller E, Glass J, et al.eds. Modern Hematology: Biology and Clinical Management 2nd ed. Totowa, NJ: Humana Press; 2007:250.
2. Rawstron AC, Orfao A, Beksac M, et al.Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93:431-438. (Pubitemid 351398645)
3. Bataille R, Robillard N, Avet-Loiseau H, et al.CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica. 2005;90:706-707. (Pubitemid 40780900)
4. Moreaux J, Hose D, Reme T, et al.CD200 is a new prognostic factor in multiple myeloma. Blood. 2006;108:4194-4197. (Pubitemid 44913292)
5. Robillard N, Pellat-Deceunynck C, Bataille R. Phenotypic characterization of the human myeloma cell growth fraction. Blood. 2005;105:4845-4848. (Pubitemid 40807312)
6. Moreau P, Robillard N, Avet-Loiseau H, et al.Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica. 2004;89:547-551. (Pubitemid 38691241)
7. Ocqueteau M, Orfao A, Almeida J, et al.Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients: implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol. 1998;152:1655-1665. (Pubitemid 28275024)
8. Rawstron AC, Owen RG, Davies FE, et al.Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol. 1997;97:46-55. (Pubitemid 27179563)
9. Terstappen LW, Johnsen S, Segers-Nolten IM, et al.Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood. 1990;76:1739-1747.
10. Perez-Persona E, Vidriales MB, Mateo G, et al.New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586-2592. (Pubitemid 47523182)
11. San Miguel JF, Gutierrez NC, Mateo G, et al.Conventional diagnostics in multiple myeloma. Eur J Cancer. 2006;42:1510-1519. (Pubitemid 44118776)
12. Sezer O, Heider U, Zavrski I, et al.Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells. Haematologica. 2001;86:837-843. (Pubitemid 32847445)
13. Mateo G, Montalban MA, Vidriales MB, et al.Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol. 2008;26:2737-2744.
14. Hundemer M, Klein U, Hose D, et al.Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transplant. 2007;40:1033-1037. (Pubitemid 350142555)
15. Bataille R, Jego G, Robillard N, et al.The phenotype of normal, reactive and malignant plasma cells: identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica. 2006;91:1234-1240. (Pubitemid 44408434)
16. Robillard N, Avet-Loiseau H, Garand R, et al.CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood. 2003;102:1070-1071. (Pubitemid 36917806)
17. Matsuda I, Mori Y, Nakagawa Y, et al.Close correlations between CD20 expression, a small mature plasma cell morphology and t(11; 14) in multiple myeloma [in Japanese]. Rinsho Ketsueki. 2005;46:1293-1297.
18. Fonseca R, Harrington D, Oken MM, et al.Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (Ä13) in multiple myeloma: an Eastern Cooperative Oncology Group study. Cancer Res. 2002;62:715-720. (Pubitemid 34126946)
19. Mateo G, Castellanos M, Rasillo A, et al.Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res. 2005;11:3661-3667. (Pubitemid 40685582)
20. Lima M, dos Anjos Teixeira M, Fonseca S, et al.Immunophenotypic aberrations, DNA content, and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies. Blood Cells Mol Dis. 2000;26:634-645. (Pubitemid 32181908)
21. San Miguel JF, Gonzalez M, Gascon A, et al.Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol. 1991;77:185-190.
22. Liu H, Yuan C, Heinerich J, et al.Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study. Leuk Lymphoma. 2008;49:306-314. (Pubitemid 351193924)
23. Lemoli RM, Fortuna A. C-kit ligand (SCF) in human multiple myeloma cells. Leuk Lymphoma. 1996;20:457-464. (Pubitemid 26096053)
24. Potti A, Ganti AK, Koch M, et al.Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma. Leuk Lymphoma. 2002;43:2427-2430. (Pubitemid 35386171)
25. Lugli A, Went P, Khanlari B, et al.Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment. Virchows Arch. 2004;444:264-268. (Pubitemid 38446439)
26. Kapoor P, Greipp PT, Morice WG, et al.Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol. 2008;141:135-148. (Pubitemid 351406208)
27. Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol. 2000;27(6 suppl 12):17-24. (Pubitemid 32164592)
28. Gertz MA, Lacy MQ, Dispenzieri A. Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev. 2004;18:17-37. (Pubitemid 38200499)
29. Garcia-Sanz R, Orfao A, Gonzalez M, et al.Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032-1037. (Pubitemid 29067869)
30. Buda G, Carulli G, Orciuolo E, et al.Two cases of plasma cell leukemia with atypical immunophenotype. Acta Haematol. 2007;118:27-29. (Pubitemid 47014337)
31. Pilarski LM, Jensen GS. Monoclonal circulating B cells in multiple myeloma: a continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin North Am. 1992;6:297-322.
32. Bergsagel DE. The role of chemotherapy in the treatment of multiple myeloma. Baillieres Clin Haematol. 1995;8:783-794. (Pubitemid 26014362)
33. Treon SP, Pilarski LM, Belch AR, et al.CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother. 2002;25:72-81. (Pubitemid 34052837)
34. Moreau P, Voillat L, Benboukher L, et al.Rituximab in CD20 positive multiple myeloma. Leukemia. 2007;21:835-836. (Pubitemid 46444580)
35. Alcindor T, Kimlinger T, Witzig TE. High expression of CD59 and CD55 on benign and malignant plasma cells. Leuk Lymphoma. 2006;47:919-921. (Pubitemid 43840650)
36. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359-7368.
37. Dispenzieri A, Gertz MA, Lacy MQ, et al.A phase II trial of imatinib in patients with refractory/relapsed myeloma. Leuk Lymphoma. 2006;47:39-42. (Pubitemid 43101722)
38. Paiva B, Almeida J, Pérez-Andres M, et al.Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom. 2010;78:239-252.
39. Raja KR, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol. 2010;149:334-351.
40. Cannizzo E, Bellio E, Sohani AR, et al.Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. Cytometry B Clin Cytom. 2010;78:231-238.
41. Durie BGM, Harousseau J-L, Miguel JS, et al.International uniform response criteria for multiple myeloma [published corrections appear in Leukemia. 2006;20:2220; and Leukemia . 2007;21:1134]. Leukemia. 2006;20:1467-1473. (Pubitemid 44264086)
42. Cserti-Gazdewich CM, Dzik WH, Dorn ME, et al.Quantitation of CD36 (platelet glycoprotein IV) expression on platelets and monocytes by flow cytometry: application to the study of Plasmodium falciparum malaria. Cytometry B Clin Cytom. 2009;76:127-134.
43. Guikema JE, Hovenga S, Vellenga E, et al.CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol. 2003;121:36-43. (Pubitemid 36461265)
44. Zhan F, Tian E, Bumm K, et al.Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood. 2003;101:1128-1140. (Pubitemid 36139388)
45. de Tute RM, Jack AS, Child JA, et al.A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma. Leukemia. 2007;21:2046-2049. (Pubitemid 47299981)
46. Sahara N, Takeshita A, Shigeno K, et al.Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol. 2002;117:882-885. (Pubitemid 34639251)
47. Lin P, Owens R, Tricot G, et al.Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121:482-488. (Pubitemid 38392955)
48. Peceliunas V, Janiulioniene A, Matuzeviciene R, et al.Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors. Cytometry B Clin Cytom. 2011;80:318-323.
49. Maurer D, Holter W, Majdic O, et al.CD27 expression by a distinct subpopulation of human B lymphocytes. Eur J Immunol. 1990;20:2679-2684.